ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 1262 • ACR Convergence 2020

    Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE

    Selcan Demir1, Jessica Li2, Laurence Magder3 and Michelle Petri4, 1Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD, 4Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
  • Abstract Number: 0519 • ACR Convergence 2020

    Thrombotic and Obstetric Associations of Non-Criteria Antiphospholipid Immunoassays That Detect Antibodies to Neutral and Negatively-Charged Phospholipid

    Rohan Willis1, E Nigel Harris2, Vijaya Murthy3, Zurina Romay-Penabad1, Alvaro Schleh4, Monica Smikle2, Karel De Ceulaer2, Anne Tebo5, Troy Jaskowski6, Marta Guerra7, David Ware Branch8, Jane Salmon7, Michelle Petri9 and Emilio Gonzalez1, 1University of Texas Medical Branch, Galveston, TX, 2University of the West Indies, Kingston, Jamaica, 3University of Texas Medical Branch, League City, TX, 4Antiphospholipid Standardization Laboratory, GALVESTON, TX, 5Department of Pathology, University of Utah, Salt Lake City, 6ARUP Laboratories, Salt Lake City, UT, 7Hospital for Special Surgery, New York, NY, 8University of Utah, Salt Lake City, 9Johns Hopkins University School of Medicine, Baltimore

    Background/Purpose: Criteria antiphospholipid (aPL) antibodies that identify antiphospholipid syndrome (APS) patients, anticardiolipin (aCL) and anti-β2glycoprotein-I (anti-β2GPI), have demonstrated inconsistent specificity and sensitivity in this regard…
  • Abstract Number: 1447 • ACR Convergence 2020

    Vitamin D Deficiency Enhances Antiphospholipid Antibody-Mediated Thrombosis in a Passive Immunization Mouse Model

    Rohan Willis1, Karen Roye-Green2, Zurina Romay-Penabad1, Elizabeth Papalardo1, Alvaro Schleh3, Vijaya Murthy4, Monica Smikle2 and Emilio Gonzalez1, 1University of Texas Medical Branch, Galveston, TX, 2University of the West Indies, Kingston, Jamaica, 3Antiphospholipid Standardization Laboratory, GALVESTON, TX, 4University of Texas Medical Branch, League City, TX

    Background/Purpose: Abnormal vitamin D levels occur frequently in antiphospholipid (APS) patients and are correlated with thrombosis. It remains unclear however if vitamin D deficiency observed…
  • Abstract Number: 0520 • ACR Convergence 2020

    Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward

    Alexandre Le Joncour1, Corinne Frere1, Isabelle Martin-Toutain1, Paul Gougis1, Pascale Ghillani-Dalbin1, Georgina Maalouf1, Matheus Vieira1, Anne-Genevieve Marcelin1, Joe-Elie Salem1, Yves Allenbach2, David Saadoun3, Olivier Benveniste4 and Patrice Cacoub1, 1APHP, paris, France, 2Sorbonne Université, Paris, Ile-de-France, France, 3AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, PAris, France, 4Sorbonne Université, paris, France

    Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…
  • Abstract Number: 1448 • ACR Convergence 2020

    Single-cell RNA Sequencing of Livedo Reticularis Skin Reveals Endothelial Pathology in Antiphospholipid Syndrome

    Hui Shi1, Allison Billi1, Rachael Wasikowski1, Kelsey Gockman1, Alex Tsoi1, Johann Gudjonsson2 and Jason Knight3, 1University of Michigan, Ann Arbor, 2University of Michigan, Ann ArborUniversity of Michigan, 3Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is a thromboinflammatory disease that can present with a variety of clinical phenotypes. Livedo reticularis is the most common skin manifestation…
  • Abstract Number: 0521 • ACR Convergence 2020

    Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?

    Flavio Signorelli1, Gustavo Balbi2, Eloisa Bonfa3, Eduardo Borba4 and Danieli Andrade5, 1Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, 2Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, 3Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
  • Abstract Number: 1450 • ACR Convergence 2020

    Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype

    Carlos Pérez-Sánchez1, M Angeles Aguirre2, Alejandra Maria Patiño-Trives1, Laura Pérez-Sanchez3, Maria Luque-Tevar1, Iván Arias de la Rosa1, María-Carmen Abalos-Aguilera1, Pedro Segui4, Javier Rodriguez-Ubreva5, Esteban Ballestar5, Nuria Barbarroja1, Eduardo Collantes-Estévez2 and Chary Lopez-Pedrera1, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 3Hospital Universitario Reina Sofía, Córdoba, Spain, 4IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, 5Josep Carreras Institute (IJC), Badalona, Spain

    Background/Purpose: 1. To develop integrated analyses of the genome-wide DNA methylation and gene expression profiles in monocytes from APS patients and assess their involvement in…
  • Abstract Number: 0522 • ACR Convergence 2020

    Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results

    Medha Barbhaiya1, Stephane Zuily2, Yasaman Ahmadzadeh3, Karen Costenbader4, Raymond Naden5 and Doruk Erkan6, 1Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, 2Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, 3Hospital for Special Surgery, New York, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, 6Hospital for Special Surgery, New York, NY

    Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria for Antiphospholipid Syndrome (APS). The methodological approach includes four…
  • Abstract Number: 1451 • ACR Convergence 2020

    Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE

    Michelle Petri1, Laurence Magder2 and Daniel Goldman1, 1Johns Hopkins University School of Medicine, Timonium, MD, 2University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
  • Abstract Number: 0523 • ACR Convergence 2020

    Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members

    Medha Barbhaiya1, Doruk Erkan2, Stephane Zuily3, Tektonidou Maria4 and Surya Seshan5, 1Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, 4National and Kapodistrian University of Athens, Athens, Greece, 5Weill Cornell Medical College, New York, NY

    Background/Purpose: Antiphospholipid antibody (aPL)-associated nephropathy (aPL-N) is recognized as a distinct complication of APS. However, it remains unclear whether pathologists worldwide use uniform diagnostic criteria…
  • Abstract Number: 1501 • ACR Convergence 2020

    Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria

    Maddalena Larosa1, Nathalie Morel2, Meriem Belhocine3, Amelia Ruffatti4, Nicolas Martin Silva5, Romain Paule6, Luc Mouthon7, Michel Dreyfus8, Jean-Charles Piette9, Odile Souchaud-Debouverie10, Catherine Deneux-Tharaux11, Vassilis Tsatsaris12, Emmanuelle Pannier Metzger13, Gaëlle Guettrot-Imbert14, Veronique Le Guern15, Andrea Doria16 and Nathalie Costedoat-Chalumeau17, 1Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, 2AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, 3Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, 4Department of Medicine, University of Padova, Padova, Veneto, Italy, 5Centre Hospitalier et Universitaire de Caen, Caen, France, 6Foch Hospital, Paris, France, 7Hopital Cochin - Paris University, Paris, France, 8CHU de Caen, Caen, France, 9Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, 10CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, 11INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, 12Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, 13Maternité Port-Royal,Hôpital Cochin, Paris, France, 14Médecine Interne,Hôpital Cochin, paris, France, 15Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, 16University of Padua, Padua, Italy, 17APHP, Université de Paris, Paris, France

    Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…
  • Abstract Number: 0524 • ACR Convergence 2020

    Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases

    Yann Nguyen1, Cécile Yelnik2, Nathalie Morel3, Romain Paule4, Pierre-Yves Hatron2, Romain Stammler5, Léo Plaçais3, Jean-Charles Piette6, Luc Mouthon7, Eric Hachulla8, Marc Lambert2, Le Guern Véronique3 and Nathalie Costedoat-Chalumeau9, 11Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, 2Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, 3National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, 4Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, 5National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, 6Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, 7National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 8Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, 9APHP, Université de Paris, Paris, France

    Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
  • Abstract Number: 1680 • ACR Convergence 2020

    Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism

    Elizabeth Sloan1 and Ayesha Zia1, 1UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: The presence of antiphospholipid antibodies, including lupus anticoagulant (LA), is a risk factor for development of venous thromboembolism (VTE) in children. The impact of…
  • Abstract Number: 0525 • ACR Convergence 2020

    Epidemiology of Thromboembolic Complications Among Hospitalized Patients with Antiphospholipid Syndrome in the United States

    Lauren Mathias1, Aditya Mantha2, Kristen Mathias3 and Glenn Ehresmann1, 1University of Southern California, Division of Rheumatology, Los Angeles, CA, 2University of Southern California, Department of Medicine, Los Angeles, CA, 3University of Chicago, Department of Medicine, Chicago, IL

    Background/Purpose: Antiphospholipid syndrome (APLS) is characterized by arterial and venous thrombosis, often in the setting of an underlying systemic disease. Few studies have described the…
  • Abstract Number: 1775 • ACR Convergence 2020

    Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies

    Hiromi Shimada1, Risa Wakiya2, Mai Mahmound Fahmy Mansour1, Shusaku Nakashima1, Mikiya Kato1, Koichi Sugihara1, Yusuke Ushio1, Tomohiro Kameda1 and Hiroaki Dobashi3, 1Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, 2Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan, 3Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: Antiphospholipid antibodies induce several obstetric complications including recurrent spontaneous abortion, preterm birth, intrauterine fetal death. EULAR recommendations for antiphospholipid syndrome (APS) indicates low dose…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology